Literature DB >> 23893969

Conditional KIAA1549:BRAF mice reveal brain region- and cell type-specific effects.

Aparna Kaul1, Yi-Hsien Chen, Ryan J Emnett, Scott M Gianino, David H Gutmann.   

Abstract

Low-grade brain tumors (pilocytic astrocytomas) that result from a genomic rearrangement in which the BRAF kinase domain is fused to the amino terminal of the KIAA1549 gene (KIAA1549:BRAF fusion; f-BRAF) commonly arise in the cerebellum of young children. To model this temporal and spatial specificity in mice, we generated conditional KIAA1549:BRAF strains that coexpresses green fluorescent protein (GFP). Although both primary astrocytes and neural stem cells (NSCs) from these mice express f-BRAF and GFP as well as exhibit increased MEK activity, only f-BRAF-expressing NSCs exhibit increased proliferation in vitro. Using Cre driver lines in which KIAA1549:BRAF expression was directed to NSCs (f-BRAF; BLBP-Cre mice), astrocytes (f-BRAF; GFAP-Cre mice), and NG2 progenitor cells (f-BRAF; NG2-Cre mice), increased glial cell numbers were observed only in the cerebellum of f-BRAF; BLBP-Cre mice in vivo. The availability of this unique KIAA1549:BRAF conditional transgenic mouse strain will enable future mechanistic studies aimed at defining the developmentally-regulated temporal and spatial determinants that underlie low-grade astrocytoma formation in children.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  astrocyte; brain tumor; genetically-engineered mice; glioma; neural stem cell; pilocytic astrocytoma

Mesh:

Substances:

Year:  2013        PMID: 23893969      PMCID: PMC3808469          DOI: 10.1002/dvg.22415

Source DB:  PubMed          Journal:  Genesis        ISSN: 1526-954X            Impact factor:   2.487


  30 in total

1.  Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.

Authors:  Da Yong Lee; Tu-Hsueh Yeh; Ryan J Emnett; Crystal R White; David H Gutmann
Journal:  Genes Dev       Date:  2010-09-28       Impact factor: 11.361

Review 2.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Authors:  Therese A Dolecek; Jennifer M Propp; Nancy E Stroup; Carol Kruchko
Journal:  Neuro Oncol       Date:  2012-11       Impact factor: 12.300

3.  Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.

Authors:  Tim Forshew; Ruth G Tatevossian; Andrew R J Lawson; Jing Ma; Geoff Neale; Babatunji W Ogunkolade; Tania A Jones; Johan Aarum; James Dalton; Simon Bailey; Tracy Chaplin; Rowena L Carter; Amar Gajjar; Alberto Broniscer; Bryan D Young; David W Ellison; Denise Sheer
Journal:  J Pathol       Date:  2009-06       Impact factor: 7.996

4.  Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.

Authors:  J P Robinson; M W VanBrocklin; A R Guilbeault; D L Signorelli; S Brandner; S L Holmen
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

5.  Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms.

Authors:  Balazs Hegedus; Biplab Dasgupta; Jung Eun Shin; Ryan J Emnett; Elizabeth K Hart-Mahon; Lynda Elghazi; Ernesto Bernal-Mizrachi; David H Gutmann
Journal:  Cell Stem Cell       Date:  2007-10-11       Impact factor: 24.633

6.  Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma.

Authors:  J Yu; H Deshmukh; R J Gutmann; R J Emnett; F J Rodriguez; M A Watson; R Nagarajan; D H Gutmann
Journal:  Neurology       Date:  2009-09-30       Impact factor: 9.910

7.  Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.

Authors:  Tu-Hsueh Yeh; Da Yong Lee; Scott M Gianino; David H Gutmann
Journal:  Glia       Date:  2009-08-15       Impact factor: 7.452

8.  Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours.

Authors:  K Jacob; S Albrecht; C Sollier; D Faury; E Sader; A Montpetit; D Serre; P Hauser; M Garami; L Bognar; Z Hanzely; J L Montes; J Atkinson; J-P Farmer; E Bouffet; C Hawkins; U Tabori; N Jabado
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

9.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

Authors:  David T W Jones; Sylvia Kocialkowski; Lu Liu; Danita M Pearson; L Magnus Bäcklund; Koichi Ichimura; V Peter Collins
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

10.  Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation.

Authors:  Liqin Zhu; Paul Gibson; D Spencer Currle; Yiai Tong; Robert J Richardson; Ildar T Bayazitov; Helen Poppleton; Stanislav Zakharenko; David W Ellison; Richard J Gilbertson
Journal:  Nature       Date:  2008-12-17       Impact factor: 49.962

View more
  9 in total

Review 1.  Pediatric gliomas as neurodevelopmental disorders.

Authors:  Suzanne J Baker; David W Ellison; David H Gutmann
Journal:  Glia       Date:  2015-12-06       Impact factor: 7.452

2.  The impact of coexisting genetic mutations on murine optic glioma biology.

Authors:  Aparna Kaul; Joseph A Toonen; Scott M Gianino; David H Gutmann
Journal:  Neuro Oncol       Date:  2014-09-21       Impact factor: 12.300

Review 3.  Pediatric low-grade gliomas: next biologically driven steps.

Authors:  David T W Jones; Mark W Kieran; Eric Bouffet; Sanda Alexandrescu; Pratiti Bandopadhayay; Miriam Bornhorst; David Ellison; Jason Fangusaro; Michael J Fisher; Nicholas Foreman; Maryam Fouladi; Darren Hargrave; Cynthia Hawkins; Nada Jabado; Maura Massimino; Sabine Mueller; Giorgio Perilongo; Antoinette Y N Schouten van Meeteren; Uri Tabori; Katherine Warren; Angela J Waanders; David Walker; William Weiss; Olaf Witt; Karen Wright; Yuan Zhu; Daniel C Bowers; Stefan M Pfister; Roger J Packer
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300

4.  The BRAF kinase domain promotes the development of gliomas in vivo.

Authors:  Clifford H Shin; Allie H Grossmann; Sheri L Holmen; James P Robinson
Journal:  Genes Cancer       Date:  2015-01

5.  Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age.

Authors:  Adam M Fontebasso; Margret Shirinian; Dong-Anh Khuong-Quang; Denise Bechet; Tenzin Gayden; Marcel Kool; Nicolas De Jay; Karine Jacob; Noha Gerges; Barbara Hutter; Huriye Şeker-Cin; Hendrik Witt; Alexandre Montpetit; Sébastien Brunet; Pierre Lepage; Geneviève Bourret; Almos Klekner; László Bognár; Peter Hauser; Miklós Garami; Jean-Pierre Farmer; Jose-Luis Montes; Jeffrey Atkinson; Sally Lambert; Tony Kwan; Andrey Korshunov; Uri Tabori; V Peter Collins; Steffen Albrecht; Damien Faury; Stefan M Pfister; Werner Paulus; Martin Hasselblatt; David T W Jones; Nada Jabado
Journal:  Oncotarget       Date:  2015-10-13

6.  KIAA1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NFκB-Mediated CCL2 Production.

Authors:  Ran Chen; Chanel Keoni; Christopher A Waker; Robert M Lober; Yi-Hsien Chen; David H Gutmann
Journal:  Neoplasia       Date:  2018-11-30       Impact factor: 5.715

Review 7.  Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas.

Authors:  Till Milde; Fausto J Rodriguez; Jill S Barnholtz-Sloan; Nirav Patil; Charles G Eberhart; David H Gutmann
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

Review 8.  Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors.

Authors:  Adam M Fontebasso; Tenzin Gayden; Hamid Nikbakht; Michael Neirinck; Simon Papillon-Cavanagh; Jacek Majewski; Nada Jabado
Journal:  Acta Neuropathol       Date:  2014-07-31       Impact factor: 17.088

9.  P2A-Fluorophore Tagging of BRAF Tightly Links Expression to Fluorescence In Vivo.

Authors:  J Edward van Veen; Daphne R Pringle; Martin McMahon
Journal:  PLoS One       Date:  2016-06-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.